May 13 2022 This Week in Cardiology May 13 2022 This Week in Cardiology
Obstructive hypertrophic cardiomyopathy and mavacamten, SGLT2 inhibitors, the triple whammy, espresso, and clinician burnout are the topics John Mandrola, MD, covers in today ’s podcast.theheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 13, 2022 Category: Consumer Health News Tags: Cardiology Commentary Source Type: news
Positive Topline Results for Dapagliflozin in HFpEF: DELIVER Positive Topline Results for Dapagliflozin in HFpEF: DELIVER
AstraZeneca says regulatory submissions will be forthcoming, potentially bringing a second SGLT2 inhibitor in this space, after empagliflozin.News Alerts (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - May 5, 2022 Category: Internal Medicine Tags: Cardiology News Alert Source Type: news
Suggestions for Successful SGLT2i Use in Glomerular Disease Suggestions for Successful SGLT2i Use in Glomerular Disease
Findings from recent trials further support the benefits of SGLT2 inhibitors in the management of glomerular disease. This review provides guidance for successful implementation.Current Opinion in Nephrology and Hypertension (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 5, 2022 Category: Consumer Health News Tags: Nephrology Journal Article Source Type: news
SGLT2 Inhibitor Safe for Kidneys in Hospitalized COVID Patients
(MedPage Today) -- Taking sodium-glucose cotransporter-2 (SGLT2) inhibitor dapagliflozin (Farxiga) didn't hinder renal outcomes for patients hospitalized with COVID-19, according to a secondary analysis of the DARE-19 trial.
Among patients with... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 29, 2022 Category: Cardiology Source Type: news
Diabetes and Heart Disease Highlights From ACC 2022 Diabetes and Heart Disease Highlights From ACC 2022
Dr Martha Gulati shares key reports from ACC 2022, including updates on SGLT2 inhibitors from the SCORED trial, chronic hypertension in pregnancy, and heart-healthy diet education in supermarkets.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 25, 2022 Category: Consumer Health News Tags: Cardiology ReCAP Source Type: news
SGLT2 Inhibitors: The Statins of the 21st Century SGLT2 Inhibitors: The Statins of the 21st Century
This overview of the development and clinical applications of SGLT2 inhibitors positions them as one of the major pharmacological advances in cardiovascular medicine in this century.European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 19, 2022 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
Combo of SGLT2 Inhibitor + GLP-1 RA Boosts Diabetes Survival Combo of SGLT2 Inhibitor + GLP-1 RA Boosts Diabetes Survival
Survival of patients with type 2 diabetes and CVD rose by 80% when they received both an SGLT2 inhibitor and GLP-1 RA, compared with either class alone.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 15, 2022 Category: Cardiology Tags: Cardiology News Source Type: news
ACC: Empagliflozin Offers Clinical Benefit in Heart Failure
WEDNESDAY, April 13, 2022 -- For patients hospitalized for acute heart failure, treatment with the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin produces clinical benefit, according to a study published online April 4 in Circulation... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 13, 2022 Category: Pharmaceuticals Source Type: news
SGLT2 Inhibitors Reduce Heart Failure Hospitalization
TUESDAY, April 12, 2022 -- For patients with heart failure, sodium-glucose cotransporter-2 (SGLT2) inhibitors reduce hospitalization for heart failure and cardiovascular death, but increase the risk of genital infections, according to a review... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 12, 2022 Category: Pharmaceuticals Source Type: news
SCORED Trial: Sotagliflozin Showed Robust MACE Benefit SCORED Trial: Sotagliflozin Showed Robust MACE Benefit
Trial results for the ' twincretin ' in patients with diabetes, CKD, and high CVD risk showed robust benefits across MACE outcomes, distinguishing sotagliflozin from the SGLT2 inhibitors.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 3, 2022 Category: Cardiology Tags: Cardiology News Source Type: news
Vascular Repair and Regeneration in Cardiometabolic Diseases Vascular Repair and Regeneration in Cardiometabolic Diseases
This review presents novel data indicating that intervention using SGLT2 inhibition or gastric bypass can restore cell-mediated vascular repair mechanisms in patients with cardiometabolic disease.European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 14, 2022 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
Finerenone + SGLT2 Inhibitor of Benefit in Diabetes With CKD? Finerenone + SGLT2 Inhibitor of Benefit in Diabetes With CKD?
Results from FIDELITY, a prespecified analysis of data from two pivotal trials of finerenone, hints of an additive benefit with SGLT2 inhibitors in patients with type 2 diabetes.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - February 28, 2022 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news
FDA Okays Empagliflozin for HF Regardless of Ejection Fraction FDA Okays Empagliflozin for HF Regardless of Ejection Fraction
The expanded indication for the SGLT2 inhibitor empagliflozin (Jardiance) now includes heart failure with mid-range or preserved left-ventricular ejection fraction — essentially all heart failure.FDA Approvals (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - February 24, 2022 Category: Cardiology Tags: Cardiology News Alert Source Type: news
SGLT2 Inhibitors May Cut Repeat Syncope in Type 2 Diabetes SGLT2 Inhibitors May Cut Repeat Syncope in Type 2 Diabetes
A prospective, multicenter study suggests that sodium-glucose cotransporter 2 (SGLT2) inhibitors improve cardiac autonomic dysfunction and reduce vaso-vagal syncope in patients with type 2 diabetes and prior syncope.First Look (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - February 16, 2022 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news
SGLT2 Inhibitors and HF Outcomes Across Patient Populations SGLT2 Inhibitors and HF Outcomes Across Patient Populations
This brief paper summarizes recent trials on the efficacy of SGLT2 inhibitors in heart failure patients with diabetes, chronic kidney disease, HFrEF, HFpEF, and worsening HF.European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 9, 2022 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
